TAZVERIK® (tazemetostat)
for your Relapsed or Refractory Follicular Lymphoma patients

TAZVERIK® (tazemetostat) for Relapsed or Refractory Follicular Lymphoma

Current Unmet Needs in Follicular Lymphoma

Mechanism of Disease and Mechanism of Action of TAZVERIK® (tazemetostat)

What are the Clinical Trials Results for TAZVERIK® (tazemetostat)

Dosing and Patient Management

Hypothetical Patient Case

Indication and Important Safety Information

TAZVERIK is indicated for the treatment of:

  • Adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies.
  • Adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options.

    These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Warnings and Precautions
  • Secondary Malignancies

The risk of developing secondary malignancies is increased following treatment with TAZVERIK. Across clinical trials of 729 adults who received TAZVERIK 800 mg twice daily, myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) occurred in 0.7% of patients. One pediatric patient developed T-cell lymphoblastic lymphoma (T-LBL). Monitor patients long-term for the development of secondary malignancies.

  • Embryo-Fetal Toxicity

Based on findings from animal studies and its mechanism of action, TAZVERIK can cause fetal harm when administered to pregnant women. There are no available data on TAZVERIK use in pregnant women to inform the drug-associated risk. Administration of tazemetostat to pregnant rats and rabbits during organogenesis resulted in dose-dependent increases in skeletal developmental abnormalities in both species beginning at maternal exposures approximately 1.5 times the adult human exposure (area under the plasma concentration time curve [AUC0-45h]) at the 800 mg twice daily dose.

Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with TAZVERIK and for 6 months after the final dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with TAZVERIK and for 3 months after the final dose.

Adverse Reactions

In 99 clinical study patients with relapsed or refractory follicular lymphoma receiving TAZVERIK 800 mg twice daily: Serious adverse reactions occurred in 30% of patients who received TAZVERIK. Serious adverse reactions occurring in ≥2% were general physical health deterioration, abdominal pain, pneumonia, sepsis, and anemia. The most common (≥20%) adverse reactions were fatigue (36%), upper respiratory tract infection (30%), musculoskeletal pain (22%), nausea (24%), and abdominal pain (20%).

Drug Interactions

Avoid coadministration of strong or moderate CYP3A inhibitors with TAZVERIK. If coadministration of moderate CYP3A inhibitors cannot be avoided, reduce TAZVERIK dose.

Avoid coadministration of moderate and strong CYP3A inducers with TAZVERIK, which may decrease the efficacy of TAZVERIK.

Coadministration of TAZVERIK with CYP3A substrates, including hormonal contraceptives, can result in decreased concentrations and reduced efficacy of CYP3A substrates.


Because of the potential risk for serious adverse reactions from TAZVERIK in the breastfed child, advise women not to breastfeed during treatment with TAZVERIK and for one week after the final dose.

Please see full Prescribing Information

Before prescribing Tazverik, please read the full Prescribing Information.

Meet the Speakers

  John M. Pagel, MD, PhD

John M. Pagel, MD, PhD

Chief of Hematologic Malignancies
Center for Blood Disorders and Stem Cell Transplantation
Swedish Cancer Institute

John Burke, MD

John Burke, MD

Associate Chair, US Oncology
Hematology Research Program
Rocky Mountain Cancer Centers

Sandra Kurtin, PhD, ANP-C

Sandra Kurtin, PhD, ANP-C

Director, Advanced Practice
Assistant Professor, Clinical Medicine and Nursing
The University of Arizona and Arizona Cancer Center

Program Objectives


Raise awareness of TAZVERIK’s indication for patients with relapsed or refractory follicular lymphoma


Provide information pertaining to dosing of TAZVERIK, drug interactions, use in special patient populations, and patient counseling information


Review the mechanism of action of TAZVERIK


Review a hypothetical FL patient case


Present TAZVERIK’s clinical trial data, including its efficacy and safety profile

© 2020 Epizyme, Inc. All rights reserved.